After a long series of delays, it seems the first trial in the federal drug adulteration and misbranding case may now come sometime in January 2022, per a status conference held on Sept. 15. Attorneys and defendants gathered both in person in the Southern District of New York and telephonically to coordinate scheduling for the first in a series of trials.
The defendants who remain in the active case (excluding those who have changed their pleas to guilty or those left off the superseding indictment in November 2020) have been divided into four groups delineating which will be tried together.
According to a document filed June 11, the groups are–
Group 1: Seth Fishman, Lisa Giannelli, Jordan Fishman
Group 2: Christopher Oakes, Marcos Zulueta, Rick Dane Jr.
Group 3: Dr. Erica Garcia, Michael Tannuzzo, Dr. Rebecca Linke
Group 4: Jason Servis, Dr. Alexander Chan
The case has been dogged with delays due in large part to the amount of evidence provided from federal investigators to the defendants, which now exceeds many terabytes and thousands of pages of information.
U.S. District Judge Mary Kay Vyskocil heard arguments from defense counsel regarding the projected date for the first trial. Originally, she had expressed a desire to conduct the first trial sometime in late 2021, but attorneys for Group 1 had conflicts with other trials being held in December. She suggested a gap had opened up in her calendar for Nov. 3 of this year, but defense attorneys balked at the fast-approaching date, leading to some testy exchanges with Vyskocil. At one point, an unidentified man using the telephonic conference option to attend the hearing could be heard saying, “I don't like this judge” before being asked to mute his line.
Defense counsel moved that the trial be conducted sometime in January 2022, pointing out that the court had already agreed they would have 60 days prior to trial to review the list of the prosecution's expert witnesses. A Nov. 3 trial date would not allow 60 days to elapse as previously ordered.
Patrick Joyce, attorney for Jordan Fishman, also registered concerns about the amount of time defense would have to review the voluminous evidence.
“As this court is aware, this is an extremely complicated case,” said Joyce. “There are a lot of issues … we're not asking for an adjournment into infinity. We're not saying next July. We're asking for two months.”
Vyskocil dismissed that concern, saying it was “not a valid reason to kick this trial” but the 60-day period of review already outlined was a good reason to delay until January. An exact date will be determined when the federal court releases its calendar.
“I do not control the trial calendar if we're still operating under these COVID-19 protocols, so I am telling you now that this case is going to trial in the first quarter,” she said. “I will request the earliest slot we can be given in the first quarter and we are going to trial. I am not going to listen to, 'Well I have something that's backed up.' … You are all on notice.”
Vyskocil did not rule on the various motions before her to exclude wiretap evidence collected by the FBI during Wednesday's status conference. Although she acknowledged considerable interest in the contents of exhibits traded in those motions, she said she could not make a determination on whether intercepted phone calls, emails, and text messages will be game at trial until the defense has had a chance to submit formal replies regarding the motions. Typically, a motion submitted by defense counsel generates a response from prosecutors, and then defense attorneys have a chance to file a formal response to the prosecution before it's considered that all arguments have been made. Vyskocil said the deadline for defense replies will be later this month, and she will endeavor to make a ruling as soon as all the arguments are in.
Read more about what we learned from new wiretap evidence in the U.S. Attorneys' response here.
A new status conference has been scheduled for Nov. 4 to allow attorneys to check in with the court regarding any remaining issues with discovery evidence.
The post First Trial In Federal Drug Misbranding Case Will Likely Come In January appeared first on Horse Racing News | Paulick Report.
